Arrhythmogenic right ventricular
KEYWORDS: arvd, ventricular, right, ventricle, disease, right ventricular, cardiac, right ventricle, tachycardia, seen, wall, involved, death, left, free wall

VT â€¢ Determine whether the VT can be interrupted via antitachycardia pacing. Regardless of the management option chosen, the individual is typically suggested to undergo lifestyle modification, including avoidance of strenuous exercise, cardiac stimulants (i.e.: caffeine, nicotine, pseudoephedrine) and alcohol. If the individual wishes to begin an exercise regimen, an exercise stress test may have added benefit. Pharmacologic management Pharmacologic management of ARVD involves arrhythmia suppression and prevention of thrombus formation. Sotalol, a beta blocker and a class III antiarrhythmic agent, is the most effective antiarrhythmic agent in ARVD. Other antiarrhythmic agents used include amiodarone and conventional beta blockers (i.e.: metoprolol). If antiarrhythmic agents are used, their efficacy should be guided by series ambulatory holter monitoring, to show a reduction in arrhythmic events. While angiotensin converting enzyme inhibitors (ACE Inhibitors) are well known for slowing progression in other cardiomyopathies, they have not been proven to be helpful in ARVD. Individuals with decreased RV ejection fraction with dyskinetic portions of the right ventricle may benefit from long term anticoagulation with warfarin to prevent thrombus formation and subsequent pulmonary embolism. Catheter ablation Catheter ablation may be used to treat intractable ventricular tachycardia. It has a 60-90% success rate.[6] Unfortunately, due to the
